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Introduction
T-cell immunoglobulin mucin 3 (TIM3) was originally identi-
fied as a molecule selectively expressed on terminally differen-
tiated interferon γ (IFNγ)-producing Type 1 CD4+ helper T 
(TH1) and Type 1 CD8+ cytotoxic T (TC1) cells.1 Upon bind-
ing to galectin-9, a soluble s-type lectin, TIM3 triggers cell 
death.2 Thus, TIM3 operates as an inhibitory molecule that 
ensures the proper termination of TH1/TC1 driven inflammation. 
Accordingly, the blockade of TIM3 signaling has been shown to 
increase IFNγ secretion and to increase the susceptibility of mice 
to develop multiple autoimmune conditions in which IFNγ-
secreting cells play a major role and to exacerbate the severity of 
the disease.1,3–5 Similarly, blocking the TIM3 signal transduction 
cascade by antibodies or RNA interference increases the secretion 
of IFNγ by activated human T cells.4,5
Recent exciting findings from us6 and others7–11 have further 
characterized TIM3 as a key regulator of the dysfunctional or 
exhausted CD8+ T-cell phenotype that arises in the course of 
chronic diseases, including chronic viral infections and cancer, in 
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both humans and experimental models. Exhausted T cells fail to 
proliferate and mediate effector functions (cytotoxicity and cyto-
kine production) in response to antigen stimulation and hence 
pose a significant barrier to the induction of productive antiviral 
and antitumor immunity.
We were the first to show that the most exhausted population 
of CD8+ T cells in cancer is marked by the expression of both 
TIM3 and the inhibitory receptor PD-1 (TIM3+PD-1+), the latter 
of which can also be found on cells that retain effector functions 
(TIM3−PD-1+).6 We also demonstrated that the co-blockade of the 
TIM3 and PD-1 signaling pathways reproducibly induces tumor 
regression, while the inhibition of PD-1 signals alone provides 
inconsistent and/or less robust antitumor effects.6,12,13 Accordingly, 
the co-blockade of TIM3 and PD-1 signals is more effective than 
the inhibition of the PD-1 signal transduction cascade alone at 
enhancing effector T-cell responses in both tumor-infiltrating 
lymphocytes (TILs) and peripheral T cells in tumor-bearing mice6 
as well as in T cells obtained from advanced melanoma patients.9 
These observations clearly indicate that TIM3 plays an important 
role in regulating the exhausted phenotype of CD8+ T cells. Still, e23849-2  OncoImmunology  Volume 2 Issue 4
tumors were FOXP3+ (Fig. 1B), indicat-
ing that the predominance of TIM3+ 
Tregs among TILs is a common feature 
across cancers of different histological 
origin. Interestingly, when we exam-
ined the presence of TIM3+ Tregs in 
the blood, spleen and tumor-draining 
lymph nodes of tumor-bearing mice, 
we found that TIM3+FOXP3+ Tregs 
are present at high frequencies only in 
tumor tissues (Fig. 1C; Fig. S1B), sug-
gesting that TIM3+ Tregs may comprise 
a specialized subset of Tregs that spe-
cifically accumulates within the tumor 
microenvironment.
Since we have previously observed 
that TIM3 and PD-1 are co-expressed 
on exhausted CD8+ TILs,6 we examined 
the expression of PD-1 on TIM3+ Tregs 
and found that PD-1 is co-expressed 
with TIM3 on Tregs (Fig. S1C). 
However, unlike TIM3, PD-1 is not dif-
ferentially expressed on CD4+FOXP3+ 
vs. CD4+FOXP3− cells (Fig. S1D). 
Thus, TIM3 marks both exhausted 
CD8+ T cells and Tregs in the tumor 
microenvironment, while PD-1 does 
not. Collectively, our data indicate that 
TIM3+ Tregs uniquely accumulate 
within tumor tissues and may comprise a 
specialized subset of tissue-resident Tregs 
that plays an important role in shaping 
antitumor immune responses in situ.
TIM3+ Tregs are more immunosuppressive than TIM3− 
Tregs. Given their predominance in the tumor microenviron-
ment, we next characterized the immunosuppressive function 
of TIM3+ Tregs. To this aim, we isolated TIM3+ and TIM3−
FOXP3+ CD4+ T cells infiltrating CT26 tumors growing in 
FOXP3-GFP knock-in mice (which express the green-fluores-
cence protein in FOXP3+ cells only) and compared their sup-
pressor functions ex vivo, in a suppression assay. We found that 
TIM3+ Tregs are approximately 2-fold more immunosuppressive 
than TIM3− Tregs (Fig. 2A). We then examined the expression of 
the immunosuppressive cytokine interleukin (IL)-10 and of cyto-
toxic effector molecules in TIM3+ and TIM3− Tregs ex vivo. We 
found that the TIM3+ Treg population contains a 2-folder higher 
frequency of IL-10-producing cells than its TIM3− counterpart 
(Fig. 2B). This was also true for TIM3+ Tregs infiltrating B16 
melanomas (Fig. S1E). In addition, we found that TIM3+ Tregs 
express more perforin, granzyme A and granzyme G than TIM3− 
Tregs (Fig. 2C). Collectively, these data indicate that TIM3+ 
Tregs represent activated tumor tissue Tregs that exhibit superior 
immunosuppressive activity as compared with TIM3− Tregs.
Modulation of TIM3+ Treg suppressor function by 
TIM3/PD-1 pathway co-blockade. The combined blockade of 
the TIM3 and PD-1 signaling pathways is highly effective in 
whether TIM3 plays any role in additional cancer-elicited mecha-
nisms of T-cell suppression remains unknown.
We have previously demonstrated that CD4+ TILs express 
TIM3,6,12 yet the significance of TIM3+CD4+ TILs in antitu-
mor immune responses was not investigated in details. Here, we 
report that TIM3 identifies intratumoral Tregs that exert robust 
immunosuppressive functions and have a major role in driving 
the development of dysfunctional/exhausted CD8+ T cells.
Results
TIM3+FOXP3+ CD4+ T cells are specifically present within 
the tumor microenvironment. We have previously observed that 
TIM3 is expressed by CD4+ TILs.6,12 However, we did not deter-
mine whether these CD4+TIM3+ TILs exhibit a FOXP3− effector 
and/or a FOXP3+ regulatory phenotype. As CD4+FOXP3+ Tregs 
are known to expand during tumor progression14,15 and to play a 
significant role in suppressing antitumor immunity,16–19 we exam-
ined the expression of TIM3 on FOXP3+ vs. FOXP3−CD4+ TILs 
infiltrating CT26 cell-derived colon carcinomas. To our surprise, 
we found that more than 50% of FOXP3+ Tregs were TIM3+ 
(Fig. 1A–C). In sharp contrast, less than 10% of CD4+FOXP3− 
TILs expressed TIM3 (Fig. S1A). Indeed, the overwhelming 
majority of CD4+TIM3+ TILs infiltrating multiple distinct solid 
Figure 1. TIM3 expression on FOXp3− and FOXp3+cD4+ tumor-infiltrating lymphocytes. 
(A) Representative co-expression of TIM3 and FOXp3 on cD4+ lymphocytes infiltrating cT26 colon 
carcinomas. (B) Frequency of FOXp3+ cells within TIM3+cD4+ cells infiltrating the indicated solid 
tumors. (C) Frequency of TIM3− and TIM3+ cells within FOXp3+cD4+ T cells found in neoplastic 
lesions, draining lymph nodes (DLNs), spleen and blood of mice bearing subcutaneous cT26 
carcinomas (n = 5). error bars indicate seM.www.landesbioscience.com OncoImmunology  e23849-3
Interestingly, two ligands of CCR5 (CCL5 and CCL4) were also 
downregulated, by 3- and 12-fold, respectively. CCR5 is known 
to play a role in the recruitment of Tregs to tumors,22 while 
CCL4 has been shown to inhibit T-cell activation by interfering 
controlling tumor growth and restoring the function to exhausted 
CD8+ T cells, whereas the inhibition of PD-1-transduced signals 
alone results in inconsistent and less robust effects.6,9,12 As TIM3 
marks both tumor-infiltrating Tregs and exhausted CD8+ TILs 
while PD-1 does not (Fig. S1D),6 the remarkable clinical effi-
cacy of the TIM3/PD-1 co-blockade might stem from combined 
effects on TIM3+ Tregs and TIM3+ exhausted CD8+ TILs. We 
therefore profiled TIM3+ Tregs from tumor-bearing mice sub-
jected to the combined blockade of the TIM3 and PD-1 signaling 
pathways (with specific monoclonal antibodies) using the mul-
tiplex NanoString nCounter technology. We found that several 
molecules associated with Treg suppressor function are downreg-
ulated in TIM3+ Tregs upon the administration of blocking anti-
bodies in vivo (Fig. 3). Perforin was downregulated by 5-fold, 
suggesting that TIM3+ Tregs exert reduced cytotoxic functions 
upon TIM3/PD-1 co-blockade. The expression of the inhibitory 
molecules PD-1 and LAG-3, which have been previously impli-
cated in supporting Treg function,20,21 was also reduced by 2.5- 
and 5-fold, respectively.
Multiple signaling pathways that impact on T-cell activation 
and trafficking were also downregulated in this setting. The 
Type II IL-1 receptor (IL-1R2), which indirectly decreases T-cell 
activation as it functions as a decoy receptor for IL-1α and IL-1β, 
was downregulated by 2-fold. The regulator of G-protein signal-
ing 16 (RGS16), which controls the activity of several chemo-
kine receptors including CCR5, was downregulated by 11-fold. 
Figure 2. Functional phenotype of TIM3+ and TIM3− FOXp3+ regulatory T cells. (A) In vitro suppression assay. FOXp3−cD4+ and cD8+ splenocytes from 
tumor-naive mice were cultured alone or together with TIM3+ or TIM3− FOXp3+cD4+ lymphocytes infiltrating cT26 carcinomas at a 1:4 regulatory T-cell 
(Treg): effector T-cell (Teff) ratio. proliferation was determined by [3h]-thymidine incorporation. Data are representative of two independent experiments. 
*p = 0.0031 (student’s t-test). (B) Left panel, representative interleukin-10 (IL-10) intracytoplasmic staining in TIM3+ and TIM3− FOXp3+cD4+ infiltrating 
cT26 carcinomas. Right panel, frequency of IL-10+ cells among TIM3+ vs. TIM3− FOXp3+ cD4+ tumor-infiltrating lymphocytes (n = 4). *p = 0.0011 (student’s 
t-test). This experiment has been repeated twice, yielding similar results. (C) expression of perforin 1, granzyme A and granzyme G in TIM3+ vs. TIM3− 
FOXp3+cD4+ TILs. Gene expression was analyzed by Nanostring ncounter. Data are representative of one out of two independent assays.
Figure 3. Downregulation of regulatory T cell (Treg) effector molecules 
in TIM3+ Tregs upon in vivo TIM3/pD-1 co-blockade. Mice bearing cT26 
carcinomas (n = 10) were treated with 100 μg anti-TIM3 antibodies 
(on day 0, 2, 4), 200 μg anti-pD-L1 antibodies (on day 0, 3, 6, 9, 12) or 
appropriate isotype-matched control antibodies, followed by the 
isolation of TIM3+FOXp3+cD4+ tumor-infiltrating lymphocytes (TILs). 
Gene expression was then analyzed by Nanostring ncounter. Data are 
represented as fold changes of treated vs. control animals.e23849-4  OncoImmunology  Volume 2 Issue 4
these data, we hypothesized that TIM3+ Tregs are specialized 
tissue-resident Tregs that accumulate early in the tumor micro-
environment where they promote the neoplastic growth by sup-
porting the development of dysfunctional CD8+ T cells.
The depletion of FOXP3+ Tregs dramatically alters the 
development of exhausted CD8+ TILs and augments effec-
tor T-cell functions. To test the hypothesis that TIM3+ Tregs 
may play a critical role in the acquisition of a dysfunctional 
phenotype by CD8+ T cells, we examined the consequences of 
a transient FOXP3+ T-cell depletion during the early phases of 
B16 melanoma growth, when TIM3+ Tregs constitute approxi-
mately 75% of tumor-infiltrating Tregs and CD8+TIM3+PD-1+ 
exhausted TILs have not yet accumulated (Fig. 4). Our kinetic 
study suggested that this occurs around day 8–12 post-implan-
tation, when the surface of neoplastic lesions is roughly 80–100 
mm2. We therefore administered the diphtheria toxin (DT) to 
mice stably expressing the DT receptor under the control of 
the FOXP3 promoter (FOXP3-DTR mice) 8 or 9 days after 
the implant of B16 cells (Fig. 5A). Our working model pre-
dicted that the depletion of Tregs would result in a decrease in 
CD8+TIM3+PD-1+ T cells. Surprisingly, we found that the fre-
quency of CD8+TIM3+PD-1+ T cells, which exhibit an exhausted 
phenotype in normal tumor-bearing mice, increased upon the 
depletion of Tregs (Fig. 5B and C). However, when we examined 
their functions, we found that CD8+TIM3+PD-1+ TILs produce 
significant amounts of IL-2, tumor necrosis factor α (TNFα), 
and IFNγ and therefore no longer exhibit an exhausted pheno-
type (Fig. 5D).
In addition to the dramatic alteration in the effector phenotype 
of CD8+TIM3+PD-1+ TILs, the depletion of Tregs promoted the 
emergence of a population of CD8+TIM3+PD-1− T cells, which 
is generally not observed in tumor-bearing mice (Fig. 5B and E). 
These CD8+TIM3+PD-1− cells produce both IFNγ and TNFα, 
indicating that they operate as effector cells (Fig. 5F). In contrast 
to the overall increase in TIM3+ cells, both the CD8+TIM3−
PD-1− and CD8+TIM3−PD-1+ TIL subpopulations are decreased 
in Treg-depleted mice (Fig. 5B; Fig. S3).
with T-cell receptor signaling.23 Thus, the co-administration of 
anti-TIM3 and anti-PD-L1 antibodies reduces the immunosup-
pressive functions of TIM3+ Tregs and may alter their homing to 
and/or retention within neoplastic lesions.
A few genes were upregulated following the co-blockade of 
TIM3 and PD-1 in vivo, including Runx1, which regulates IFNγ 
and IL-2 signaling in Tregs,24 and two members of the IFN-
regulatory factor transcription factor family, i.e., Irf5 and Irf7. 
These latter observations suggest a previously unrecognized role 
for IRFs in the regulation of Treg function.
Among the factors modulated by the co-blockade of TIM3 
and PD-1 in vivo, IL-10 is of special interest. We have shown that 
TIM3+ Tregs produce high amounts of IL-10 (Fig. 2; Fig S1E), 
and this cytokine has previously been implicated in the devel-
opment of T-cell exhaustion during chronic viral infection 
(reviewed in ref. 25). Taken together, these observations raised 
the possibility that TIM3+ Tregs may have a role in promoting 
T-cell dysfunction in the tumor microenvironment.
Relationship between TIM3+ Tregs, exhausted CD8+ T cells 
and tumor growth. To address whether TIM3+ Tregs may have 
a role in promoting T-cell exhaustion, we performed a kinetic 
analysis of intratumoral TIM3+ Tregs and exhausted CD8+ 
TIM3+PD-1+ T cells during tumor progression. Interestingly, 
we found that TIM3+ Tregs are the dominant Treg population 
at all time points in both the B16 melanoma and CT26 colon 
carcinoma models (Fig. 4A; Fig. S2A). Moreover, TIM3+ Tregs 
clearly accumulate in parallel to the growth of B16 melanoma.
We next examined the CD8+ T-cell compartment. It is gen-
erally recognized that the presence of exhausted CD8+ T cells 
strongly correlates with tumor growth. As expected, we found 
that TIM3+PD-1+ CD8+ cells, which represent the most 
exhausted CD8+ TILs, are present at a very low frequency within 
small B16 melanoma and CT26 colon carcinoma but accumulate 
steadily along with tumor growth (Fig. 4B; Fig. S2B). Overall, 
our kinetic studies show that TIM3+ Tregs dominate the Treg 
population and that the presence of TIM3+ Tregs precedes the 
appearance of exhausted CD8+ TIM3+PD-1+ TILs. Based on 
Figure 4. Intratumoral accumulation of TIM3-expressing regulatory T cells and exhausted cD8+ T cells during tumor progression. (A and B) Tumor-
infiltrating lymphocytes were harvested from B16F10 melanoma-bearing mice at different time points post-implantation and subjected to flow 
cytometry. (A) Frequency of TIM3+ and TIM3− cells among FOXp3+cD4+ TILs. The pearson R values for TIM3+ and TIM3− regulatory cells (Tregs) are 
0.808 and -0.8085, respectively. (B) Frequency of cD8+ TILs subpopulations expressing TIM3 and pD-1. For cD8+TIM3+pD-1+ TILs, R = 0.9107; for 
cD8+TIM3+pD-1+ TILs, R = 0.3022, for cD8+TIM3−pD-1− TILs, R = −0.8433.www.landesbioscience.com OncoImmunology  e23849-5
The examination of the CD4+ cell 
compartment revealed drastic altera-
tions affecting the CD4+FOXP3− 
effector T-cell population. In 
particular, following the depletion of 
Tregs we observed the emergence of a 
significant CD4+FOXP3−TIM3+ cell 
population. This cell subset was pres-
ent at a very low frequency in control 
tumor-bearing mice (Fig. 5B and G). 
These CD4+FOXP3−TIM3+ cells 
are mostly IFNγ producers, de facto 
accounting for the overall increase 
in IFNγ-producing cells among 
CD4+FOXP3− TILs in Treg-depleted 
mice (Fig. 5H). Collectively, these 
observations indicate that FOXP3+ 
Tregs, whose tumor-infiltrating subset 
mostly display a TIM3+ phenotype, 
support the development of exhausted 
CD8+ T cells and limit the expansion 
of both CD4+ and CD8+ effector T 
cells that secrete pro-inflammatory 
cytokines (IFNγ and TNFα) within 
the tumor microenvironment.
Synergy between TIM3 blockade 
and FOXP3+ Treg depletion. Our 
data indicate that CD4+ and CD8+ 
IFNγ-producing effector T cells 
emerge in tumor-bearing mice upon 
the depletion of Tregs (Fig. 5). These 
cells are not exhausted but rather 
express TIM3 as a consequence of 
their activation and differentiation 
toward an IFNγ-producing effector 
phenotype. If this were indeed the 
case, TIM3+ effector T cells should 
be subjected to regulation by TIM3-
transduced signals and hence the 
blockade of TIM3 in Treg-depleted 
mice would provide additional ther-
apeutic benefits as compared with 
those provided by the depletion of 
Tregs. As a matter of fact, we found 
that while a single dose of DT to 
CT26 colon carcinoma-bearing 
FOXP3-DTR mice delays tumor 
growth only transiently, the adminis-
tration of TIM3-blocking antibodies 
to Treg-depleted mice results in sig-
nificant and sustained tumor regres-
sion (Fig. 6A). The synergistic effects 
of Treg depletion plus TIM3 block-
ade were also observed in both MC38 
carcinoma and B16 melanoma mod-
els (Fig. S4A). Lastly, we observed 
Figure 5. FOXp3+ T-cell depletion dramatically alters the accumulation of exhausted cD8+ cells and the 
effector T-cell phenotype in the tumor microenvironment. (A–H) B16F10 melanoma cells were implant-
ed in mice expressing the diphtheria toxin (DT) receptor (DTR) under the control of the FOXp3 promoter 
(FOXp3-DTR mice). DT or pBs was then injected on days 8/9 post tumor-implantation. (A) effect of 
FOXp3+ T-cell depletion on tumor growth (mean ± seM, n = 10). (B) Representative FAcs data showing 
the expression of TIM3 on cD4+ and cD8+ tumor-infiltrating lymphocytes (TILs) as purified from control 
and DT-treated tumor-bearing mice on day 14. (C–H) Frequency of cD8+TIM3+pD-1+ TILs [(C), n = 10]; 
TIM3+pD-1+ TILs producing interleukin-2 (IL-2), tumor necrosis factor α (TNFα), or interferon γ (IFNγ) 
[(D), n = 8]; cD8+TIM3+pD-1− TILs [(E), n = 10]; TIM3+pD-1− TILs producing TNFα and IFNγ [(F), n = 8]; 
cD4+TIM3+FOXp3− TILs [(G), n = 10]; and IFNγ-producing cells within cD4+FOXp3− TILs in control vs. DT-
treated tumor-bearing mice. All data except those in (H) are pooled from three independent experi-
ments. error bars indicate seM *p = 0.0165, **p = 0.0001, ***p < 0.0001, ****p = 0.0047 (student’s t-test). 
In (H), data pooled from two independent experiments are shown, with n = 4 for experiment 1 and 
n = 3 for experiment 2. *****p = 0.0173, ******p = 0.0437 (student’s t-test).e23849-6  OncoImmunology  Volume 2 Issue 4
and infected by the hepatitis C virus.27 Interestingly, in con-
cordance with our findings, CD4+TIM3+FOXP3+ cells can be 
found among TILs but not in the peripheral blood of NSCLC 
patients, and the presence of TIM3+ Tregs correlates with poor 
clinical prognosis.
TIM3+ Tregs have recently been detected within allografted 
tissue during graft rejection.28 There are some similarities between 
the TIM3+ Tregs that arise during such an acute inflammatory 
response and those that develop during cancer-associated chronic 
inflammation, but also notable differences. In both cases, TIM3+ 
Tregs exert more robust immunosuppressive functions and 
express higher levels of effector molecules (such as IL-10) as com-
pared with their TIM3− counterparts. However, TIM3+ Tregs 
constitute less than half of the Treg population that develop in 
response to allograft and appear to be short-lived. It has indeed 
been proposed that in this setting TIM3 operates as a death-
inducing molecule, eliminating highly immunosuppressive Tregs 
and allowing for the re-establishment of immune homeostasis. In 
stark contrast, TIM3+ Tregs clearly constitute the predominant 
Treg population throughout all phases of tumor progression. The 
fact that TIM3 does not eliminate these cells likely represents yet 
another example of deregulation that arises in chronic diseases, 
similar to the persistence of TIM3+ exhausted CD8+ T cells in 
cancer.
A deeper understanding of the mechanisms whereby TIM3 
affects the function of Tregs and promotes T-cell exhaustion will 
prove critical as TIM3 moves forward as a candidate target for 
anticancer immunotherapy. Our NanoString profiling data show 
that several molecules that support the function of Tregs (IL-10, 
perforin, PD-1, LAG-3) are downregulated upon the co-blockade 
that this synergy is completely abolished when either CD4+ or 
CD8+ T cells are depleted (Fig. 6B; Fig. S4B), indicating that 
both the CD4+ and CD8+ effector T cells that emerge upon Treg 
depletion play a major role in mediating tumor regression in this 
experimental setting.
Discussion
In addition to restoring the effector activity of exhausted T cells, 
interfering with regulatory T-cell function is highly desirable in 
clinical settings. Our data indicate that TIM3 marks intratu-
moral Tregs and that the co-blockade of the TIM3 and PD-1 
signaling pathways results in the downregulation of effector 
molecules in TIM3+ Tregs. Taken together with the fact that 
TIM3 marks intratumoral exhausted CD8+ T cells and that the 
simultaneous inhibition of TIM3- and PD-1-transduced signals 
restores the function to these cells,6 these observations position 
TIM3 as an ideal candidate for cancer immunotherapy. Our 
data suggest that TIM3 inhibition early during tumor devel-
opment would mainly target tumor-infiltrating TIM3+ Tregs, 
de facto interfering with their immunosuppressive function and 
inhibiting the development of CD8+ T-cell exhaustion. TIM3 
blockade at later time points would additionally target exhausted 
CD8+ T cells and restore their effector functions. Unlike the 
global inhibition of FOXP3+ cells, anti-TIM3 antibodies would 
selectively target intratumoral Tregs, lessening the potential for 
undesirable autoimmune side effects. In this sense, the clinical 
relevance of TIM3+ Tregs as an immunotherapeutic target is sup-
ported by the recent observation of CD4+TIM3+FOXP3+ cells 
in patients affected by non-small cell lung cancer (NSCLC)26 
Figure 6. synergistic effects of TIM3 blockade and FOXp3+ regulatory T-cell depletion. (A and B) cT26 colon carcinoma cells (1 × 105) were implanted 
in mice expressing the diphtheria toxin (DT) receptor (DTR) under the control of the FOXp3 promoter (FOXp3-DTR mice) and either 0.5 μg DT or pBs 
was injected on day 12 post-tumor implantation. The anti-TIM3 antibody RMT3-23 (250 μg) or an appropriate isotype-matched control antibody (cIg) 
was given every 4 d from day 12 to day 24 post-tumor implantation. (A) effects of FOXp3+ T-cell depletion and anti-TIM3 antibodies on tumor growth. 
*pBs/cIg vs. DT/cIg, p = 0.0079 on day 24; **DT/cIg vs. DT/RMT3-23, p = 0.0593 on day 24, p = 0.0362 on day 26, p = 0.0273 on day 28, p = 0.0362 on day 
40. (B) Mice were treated as in (A) in combination with either an anti-cD8β or an anti-cD4 antibody. *DT/RMT3-23 vs. DT/RMT3-23/anti-cD4, p = 0.0079 
on day 24, p = 0.0119 on day 28, p = 0.0079 on day 32, p = 0.0119 on day 36; **DT/RMT3-23 vs. DT/RMT3-23/anti-cD8, p = 0.0079 on day 24, p = 0.0119 
on day 28, p = 0.0079 on day 32. Tumor sizes are represented as mean ± seM. Both experiments have been repeated twice. statistical differences were 
calculated by Mann-Whitney analyses at the indicated time points.www.landesbioscience.com OncoImmunology  e23849-7
indicate that TIM3 marks highly suppressive Tregs that are pres-
ent uniquely within the tumor microenvironment, where they 
play a role in shaping antitumor immune responses. Thus, our 
observations increase the potential value of TIM3 as a target for 
anticancer immunotherapy.
Materials and Methods
Mice. Six- to 12-week old female mice were used in all stud-
ies. BALB/c and C57BL/6 mice were purchased from The 
Jackson Laboratory. FOXP3-DTR KI C57BL/6 mice were 
kindly provided by Dr. Alexander Y. Rudensky. These mice 
were backcrossed > 7 times onto BALB/c mice and it was deter-
mined that this strain accepted BALB/c tumors. IL-10-Thy1.1 
C57BL/6 mice were kindly provided by Dr. Casey T. Weaver. 
FOXP3-GFP KI C57BL/6 mice were generated in Dr. Kuchroo’s 
laboratory and backcrossed onto the BALB/c background. 
DEREG mice on a C57BL/6 background were kindly provided 
by Dr. Tim Sparwasser.18 All experiments were approved and 
conducted according to the guidelines set forth by the Harvard 
Medical Area Standing Committee on Animals and The Peter 
MacCallum Animal Experimentation Ethics Committee.
Antibodies and reagents. Anti-TIM3 (RMT3-23, kindly pro-
vided by Hideo Yagita, Juntendo University) and isotype con-
trol (rat IgG2a) antibodies were purchased from BioXCell. The 
following fluorochrome-conjugated antibodies were purchased 
from Biolegend: anti-CD8a (53-6.7), anti-CD4 (RM4-5), anti-
CD45.2 (104), anti-PD-1 (RMP1-30), anti-FOXP3 (MF-14 and 
FJK-16s), anti-IFNγ (XMG1.2), anti-TNFα (MP6-XT22) and 
anti-IL-10 (JES5-16E3). Anti-TIM3 (8B.2C12 and RMT3-23) 
and anti-IL-2 (JES6-5H4) antibodies were purchased from 
eBioscience. The anti-TIM3 5D12 antibody was generated in 
V.K.K.’s laboratory and conjugated to phycoerythrin (PE) and 
allophycocyanin (APC) by BioLegend.
Tumor experiments. CT26, B16F10, MC38, A20 and 
RENCA cells were purchased from ATCC. AT3, EO771, 4T1, 
4T1.2 and DA3 mammary tumors were derived and maintained 
as previously described.31 BALB/c MCA-1 cells were derived 
from a sarcoma induced in BALB/c mice by methylcholanthrene 
(MCA). CT26 and MC38 (1 × 106), B6F10 and AT3 (5 × 105), 
A20 (2 × 105), BALB/c MCA-1 and DA3 (1 × 105), 4T1 and 
4T1.2 (5 × 104) were implanted s.c. in the flanks of mice. EO771 
(5 × 105) and RENCA (2 × 105) were implanted orthotopically. 
Tumor size was measured in two dimensions by a common cal-
iper and is reported here as the product of two perpendicular 
diameters. Tumors arising in wild-type C57BL/6 mice treated 
with MCA (MCA de novo) or C57BL/6 MMTV-PyMT mice 
were also harvested and assessed for TILs. For the depletion of 
FOXP3+ cells, FOXP3-DTR mice were implanted with B16F10 
cells on day 0 and treated with 50 μg/kg DT i.p. on days 8 and 9. 
For the studies examining the synergy between anti-TIM3 anti-
bodies and Treg depletion, FOXP3-DTR mice were treated 
with DT on day 12, and 250 μg anti-TIM3 RMT3-23 or iso-
type control antibodies were given on days 12, 16, 20 and 24. In 
some groups of mice, 100 μg anti-CD4 (GK1.5) or anti-CD8β 
(53.5.8) were given i.p. on days 11, 12, 19 and 26.
of TIM3 and PD-1 signaling pathways. As IL-10 has been impli-
cated in T-cell exhaustion in chronic viral infection,25 it is possi-
ble that this cytokine mediates one mechanism by which TIM3+ 
Tregs drive the development of CD8+ T-cell exhaustion in cancer. 
PD-1 and LAG-3 have been shown to support Treg function, yet 
they are also expressed on exhausted CD8+ T cells to operate as 
inhibitory receptors. All these observations point to an ongoing 
conundrum in the field: how do molecules that inhibit effector 
T cells support Treg function? Our data support the role of such 
molecules in Treg suppressor function and open the possibility 
that the signaling pathways that are elicited in Tregs by these fac-
tors play a prominent role in promoting T-cell exhaustion.
We found that several molecules affecting T-cell trafficking 
to and/or retention within the tumor tissue (e.g., CCL4, CCL5, 
RGS16) are downregulated following the co-inhibition of the 
TIM3 and PD-1 signaling pathways. The expression of these 
molecules on TIM3+ Tregs could account, at least in part, for 
the high frequency of TIM3+ Tregs in the tumor microenviron-
ment. In addition, the expression of galectin-9 on neoplastic cells 
including B16 melanoma and CT26 colon carcinoma cells,6,12 
may also influence the retention of TIM3+ Tregs in the tumor 
tissue. Whether galectin-9/TIM3 interactions play a role in the 
promotion of T-cell exhaustion by TIM3+ Tregs remains to be 
determined.
We also found that a few genes are upregulated in response to 
the co-blockade of TIM3- and PD-1-transduced signals in vivo, 
including Runx1, Irf5 and Irf7. RUNX1 normally activates IL-2 
and IFNγ signaling, but in Tregs appears to mediate a reverse 
effect owing to its association with FOXP3.24 As a possibility, the 
upregulation of Runx1 in TIM3+ Tregs may increase the amount 
of free Runx1, thereby favoring the activation of IL-2/IFNγ sig-
naling. IRF5 and IRF7 are mediators of Type 1 IFN signaling 
that have been primarily characterized in macrophages. Our 
findings suggest a role for these factors in the regulation of Treg 
suppressor functions.
The prophylactic depletion of Tregs results in the eradica-
tion of some tumors, such as leukemia, sarcoma and myeloma.29 
However, their therapeutic depletion (once neoplastic lesions 
are established) is often scarcely effective, even when combined 
with other immunotherapeutic approaches.30 In contrast, we have 
shown that the depletion of Tregs in mice bearing established 
tumors and the blockade of TIM3 signaling exert synergistic anti-
neoplastic effects, even against poorly immunogenic B16 mela-
nomas. Interestingly, the antitumor activity of TIM3 blockade 
coupled to Treg depletion, like that of TIM3 inhibition alone,12 
was completely abolished upon the depletion of either CD4+ or 
CD8+ T cells. TIM3 represents an important target on both CD4+ 
and CD8+ effector T cells and either subset alone is capable of 
significant antitumor activity. Our findings provide the first ratio-
nale for combining TIM3-blocking antibodies with Treg-targeted 
therapies that are already approved for use in cancer patients.17
The relative importance of TIM3 in Tregs vs. exhausted 
T cells for antitumor immunity remains unclear. In order to con-
clusively address this issue, the generation of a Tim3flox/flox mouse 
in which the conditional deletion of Tim3 in Tregs vs. CD8+ 
T cells can be achieved is required. Nevertheless, our data clearly e23849-8  OncoImmunology  Volume 2 Issue 4
Technologies, Inc.). Data were first normalized with respect to 
the geometric mean of the positive control spike counts (provided 
by the manufacturer) then relative to four reference genes (Actb, 
Gapdh, Hprt and Tubb5). A background correction was done by 
subtracting the mean + 2 SDs of eight negative control counts 
(provided by the manufacturer) and eliminating conditions that 
were < 1.
Statistical analyses. Statistical analyses were performed using 
the Prism 5.0 software (GraphPad Software, Inc.). Student’s 
t-tests and linear regression analyses were applied when appropri-
ate. Statistical differences between tumor sizes of different mice 
groups were determined by Mann-Whitney tests. p values < 0.05 
were considered as statistically significant.
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Lymphocyte isolation. For phenotypic and functional 
assays, TILs were isolated as previously described.6,12 Briefly, 
tumors were dissected, dissociated in a gentle MACS dissociator 
(Miltenyi Biotec) and then digested with collagenase D prior to 
separation on a discontinuous Percoll gradient (GE Healthcare). 
Splenocytes and lymphocytes from ipsilateral inguinal lymph 
nodes (draining lymph nodes) were also isolated and character-
ized in some experiments.
Flow cytometry. Single-cell suspensions were stained 
for surface markers and—after fixation—for intracellu-
lar FOXP3 using an anti-FOXP3 staining kit (eBioscience). 
7-Aminoactinomycin D (7AAD) was employed to exclude dead 
cells from the analysis. Cytoplasmic cytokine staining was con-
ducted as previously described.6 All data were collected on an 
LSR II (BD) or Loader Canto (BD) fluorometer and analyzed 
with FlowJo software (Tree Star, Inc.).
In vitro suppression assays. TIM3+FOXP3+ and 
TIM3−FOXP3+ CD4+ cells were sorted from TILs along with 
splenic FOXP3−CD4+ cells and CD8+ cells to be used as effector 
T cells. TIM3+ or TIM3−FOXP3+ Tregs were then cultured with 
1.5 × 104 of CD4+/CD8+ effector T cells at 1:4 ratio in the pres-
ence of 1 μg/ml soluble anti-CD3 antibody and 7.5 × 104 irra-
diated splenocytes obtained from a non-tumor bearing mouse. 
After 48 h, cells were pulsed with [3H]-thymidine and harvested 
18 h later. [3H]-Thymidine incorporation was measured on a 
micro β counter.
Gene expression analyses by NanoString. CT26 tumor cells 
were implanted in FOXP3-GFP KI mice. For the analysis of 
TIM3+ and TIM3−FOXP3+ TILs ex vivo, cells were isolated by 
cell sorting on day 16 post-tumor implantation and immediately 
lysed in RLT buffer (Qiagen). For the analysis of TIM3+ Treg 
upon TIM3/PD-1 co-blockade in vivo, CT26 carcinoma-bear-
ing mice were treated with anti-TIM3 plus anti-PD-L1 or isotype 
control antibodies as previously described.6 On day 16 post-
tumor implantation, CD4+TIM3+FOXP3+ TILs were isolated by 
cell sorting and immediately lysed in RLT buffer. Cell lysates 
were hybridized with a custom made CodeSet. Barcodes were 
counted (1150 fields of view per sample) on an nCounter Digital 
Analyzer following the manufacturer’s protocol (NanoString 
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